[99mTc]Tc-DB8

The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer.
The primary objective are:
To assess the distribution of [99mTc]Tc- DB8 in normal tissues and tumors at different time intervals.
To evaluate dosimetry of [99mTc]Tc- DB8.
To study the safety and tolerability of the drug [99mTc]Tc- DB8 after a single injection in a diagnostic dosage.
The secondary objective are:
1. To compare the obtained [99mTc]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.